These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Association Between Plasma Rituximab Concentration and the Risk of Major Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides During Rituximab Maintenance Therapy. Khoudour N; Delestre F; Jabot-Hanin F; Jouinot A; Nectoux J; Letouneur F; Izac B; Vidal M; Guillevin L; Puéchal X; Charles P; Terrier B; Blanchet B Arthritis Rheumatol; 2023 Nov; 75(11):2003-2013. PubMed ID: 37134130 [TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054 [TBL] [Abstract][Full Text] [Related]
6. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Iklé D; Villarreal M; Jepson B; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH; Arthritis Rheumatol; 2014 Nov; 66(11):3151-9. PubMed ID: 25047592 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA; Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823 [TBL] [Abstract][Full Text] [Related]
8. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Smith RM; Jones RB; Specks U; Bond S; Nodale M; Al-Jayyousi R; Andrews J; Bruchfeld A; Camilleri B; Carette S; Cheung CK; Derebail V; Doulton T; Ferraro A; Forbess L; Fujimoto S; Furuta S; Gewurz-Singer O; Harper L; Ito-Ihara T; Khalidi N; Klocke R; Koening C; Komagata Y; Langford C; Lanyon P; Luqmani R; McAlear C; Moreland LW; Mynard K; Nachman P; Pagnoux C; Peh CA; Pusey C; Ranganathan D; Rhee RL; Spiera R; Sreih AG; Tesar V; Walters G; Wroe C; Jayne D; Merkel PA; Ann Rheum Dis; 2023 Jul; 82(7):937-944. PubMed ID: 36958796 [TBL] [Abstract][Full Text] [Related]
9. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368 [TBL] [Abstract][Full Text] [Related]
15. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC; J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429 [TBL] [Abstract][Full Text] [Related]
16. Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial. Zonozi R; Cortazar FB; Jeyabalan A; Sauvage G; Nithagon P; Huizenga NR; Rosenthal JM; Sipilief A; Cosgrove K; Laliberte KA; Rhee EP; Pendergraft WF; Niles JL Ann Rheum Dis; 2024 Feb; 83(3):351-359. PubMed ID: 38123922 [TBL] [Abstract][Full Text] [Related]
17. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA; J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177 [TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomized controlled trials. Lee YH; Song GG Int J Clin Pharmacol Ther; 2022 Feb; 60(2):97-105. PubMed ID: 34622770 [TBL] [Abstract][Full Text] [Related]